Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Specific T- Lymphocytes

PreclinicalBiologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenovirusEnrolling by invitation

AdenovirusPreclinical

Enrolling by invitation

Clinical

Trials by Indication[1]

Adenovirus1 trial

Anti-viral T-cell Therapy by Gamma Capture for High-risk Patients With Acquired or Inherited Immune Defects

Enrolling by invitation·PPaul Szabolcs·Preclinical·NCT06027879·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Specific T- Lymphocytes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Specific T- Lymphocytes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Specific T- Lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Paul Szabolcs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: PPaul Szabolcs

Related News